Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | FABP4 | P15090 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304152 | 0.95 | MAPT (0.56) | MAPTGAATDP1MEN1KMT2A | |
| SCHEMBL5697158 | 0.91 | HPGD (0.60) | MAPTGAATDP1MEN1KMT2A | |
| SCHEMBL29940926 | 0.91 | HPGD (0.60) | MAPTGAATDP1MEN1KMT2A | |
| SCHEMBL23369883 | 0.90 | MEN1 (0.52) | MAPTGAATDP1MEN1KMT2A | |
| SCHEMBL29653984 | 0.88 | MAPT (0.54) | MAPTGAATDP1MEN1KMT2A | |
| SCHEMBL108882 | 0.88 | MAPT (0.54) | MAPTGAATDP1MEN1KMT2A | |
| SCHEMBL1713041 | 0.88 | HTT (0.56) | MAPTGAATDP1MEN1KMT2A | |
| SCHEMBL29511793 | 0.85 | HTT (0.59) | MAPTGAATDP1MEN1KMT2A | |
| SCHEMBL183017 | 0.85 | HTT (0.59) | MAPTGAATDP1MEN1KMT2A | |
| SCHEMBL29011651 | 0.84 | GAA (0.46) | MAPTGAATDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991997-B1 | TRANSITION METAL COMPLEXES WITH CARBENE LIGANDS AND THE USE THEREOF IN OLEDS | UDC IRELAND LTD (IE) | 2018-02-21 | — | — | EP | disclosed |
| EP-3027629-B1 | LUMINESCENT DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES | UDC IRELAND LTD (IE) | 2017-06-14 | — | — | EP | disclosed |
| US-8017774-B2 | Producing method for iridium complex | CANON KABUSHIKI KAISHA (JP) | 2011-09-13 | — | — | US | disclosed |
| WO-2010037667-A1 | COMPLEX SALTS | BASF SE (DE) | 2010-04-08 | — | — | WO | disclosed |
| US-20070232803-A1 | PRODUCING METHOD FOR IRIDIUM COMPLEX | CANON KABUSHIKI KAISHA (JP) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232803-A1 | PRODUCING METHOD FOR IRIDIUM COMPLEX | LAGE3, EML4, INTS9 | MAPT 1110/4885GAA 3056/4885TDP1 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.